Krensavage Asset Management’s BioNTech BNTX Stock Holding History

Krensavage Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.54M	Hold	59,523	–	–	2.1%	11
2026 Q1	$5.29M	Sell	59,523 -40,000	-40%	-$4.11M	2.07%	13
2025 Q4	$9.47M	Buy	99,523 +20,157	+25%	+$2.03M	3.35%	12
2025 Q3	$7.83M	Buy	79,366 +5,984	+8%	+$640K	3.33%	12
2025 Q2	$7.81M	Sell	73,382 -14,181	-16%	-$1.43M	4.14%	10
2025 Q1	$7.97M	Sell	87,563 -1,100	-1%	-$123K	4.41%	10
2024 Q4	$10.1M	Sell	88,663 -4,920	-5%	-$561K	5.98%	8
2024 Q3	$11.1M	Sell	93,583 -38,710	-29%	-$3.56M	6.23%	7
2024 Q2	$10.6M	Buy	132,293 +12,293	+10%	+$1.12M	4.88%	8
2024 Q1	$11.1M	Buy	+120,000	New	+$11.5M	4.91%	9

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Krensavage Asset Management's BNTX Position: Q2 2026 in Review

Krensavage Asset Management held its BioNTech (BNTX) position steady in Q2 2026 at 59,523 shares worth $5.54M. The position accounts for 2.1% of the portfolio, ranked #11.

Krensavage Asset Management first reported a position in BNTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.1M in Q3 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Krensavage Asset Management held 59,523 shares of BioNTech worth $5.54M as of Q2 2026.
Krensavage Asset Management left its BioNTech share count unchanged in Q2 2026.
BioNTech made up 2.1% of Krensavage Asset Management's portfolio in Q2 2026, its #11 holding.
Krensavage Asset Management first reported a position in BioNTech in Q1 2024 and has held it in 10 quarters since.
Krensavage Asset Management's BioNTech position peaked at $11.1M in Q3 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Krensavage Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.